Hercules Technology Growth Capital Inc.

Hercules Technology Growth Capital is a Private Equity company founded in 23 Headquartered in Palo Alto California with additional offices in Boston Boulder New York and McLean. The firm manages an evergreen structure and primarily provides high-growth companies in the life science space with senior secured debt financing. The firm can allocate up to $5 million per investment. The firm is very flexible with deal structures that can be customized to help companies reach their key milestones. The firm primarily invests in companies headquartered in the US but has the ability to invest overseas as well.
Janice Borque
Managing Director Life Sciences 

HInext LLC United States

Healthcare Software focusing in on Mental health & Addictions. The main goal is to place these individuals on a path to recovery.

TREAT product line is commercially available as an EHR serving the unique needs of community behavioral health, rehabilitation, and other community-based providers. The design of our system is centered on a client-centered recovery model principle with best practice assessments linked to an interdisciplinary plan of care which is at the core of our methodology. TREAT’s modules create a record of client care that functions at multiple levels and builds upon itself. From assessments, to care planning, to documentation, to decision support, TREAT provides an integrated solution centered on client care.

Assessment Tools

Our TREAT product has a catalog of over 120 different assessment tools, and can be customized to include new tools upon request. Assessments are linked with our Interdisciplinary Plan of Client Care (IPCC) and Progress Notes modules to offer a truly integrated approach to patient care.

Website:
www.treatehr.com
Year Founded
2012
Main Sector
Medtech Subsector
Medtech Phase of Development
Technology Overview
Our TREAT product has a catalog of over 120 different assessment tools, and can be customized to include new tools upon request. Assessments are linked with our Interdisciplinary Plan of Client Care (IPCC) and Progress Notes modules to offer a truly integrated approach to patient care. TREAT includes such noteworthy tools as the New York Common Assessment of Need (NYCAN), the ADAT tool suite (Addictions assessments), the PHQ-9, we will shortly be incorporating the Patient Activation Measure (PAM-13), and we uniquely offer the Metabolic Health Monitor, which tracks metabolic functioning for clients on second-generation antipsychotic medications.
Alliance & Collaborations
GSI health
Supporting Metrics or Evidence
TREAT’s IPCC and Progress Notes modules offer integrated Best Practice Guidelines (BPGs) developed in partnership with researcher Dr. Diane Doran at the University of Toronto. This module incorporates best practice guidelines into the care plan, delivering vital, pertinent guidelines to care givers at the point in time when they are making treatment decisions. The BPG options are available as canned-text which is accessed automatically using an incremental search feature. This database can be managed by the administrator, so any updates or organization specific best practices can be incorporated directly into the TREAT system. The standardization provided by this feature offers allows clinical decision support professionals to report against these text fields and improve the organization’s practices to achieve better client care. For example, these reports can help professionals to measure the effectiveness of certain interventions in the treatment of specific issues.
Current Financing Needs
$1Million
Current Investors
friends and family
IP Status
Treat as Clear
Recent Milestones
implementation with one of largest US providers
Management Team Highlights
Peter Catford, President Peter has been active in the healthcare computer consulting and management industry for over 30 years. Peter Co-founded a consulting company in the 1976 that provided technical consulting expertise to fortune 500 companies. The company later transitioned into Baxter Corporation’s healthcare division, where he was responsible for managing a technical group of 28 professionals. The group was responsible for software product development, implementation and installation in Canadian hospitals and healthcare institutions. Peter then moved to co-develop a strategy to integrate the information services departments between Mount Sinai Hospital and The Toronto Hospital. In 1997, Peter founded HInext Inc. to offer consulting and software development primarily focused on information healthcare solutions to healthcare institutions and hospitals across Canada. During the first few years of the business, Peter took an active role as the CIO in the Center for Addiction and Mental Health (CAMH). Peter managed the business information and intelligence systems and established a strategy and the architecture for electronic health record implementation at CAMH. Currently, Peter continues to lead and manage HInext and is committed to growing the company into a North American leader in healthcare Information Systems. Linas Balaisis CA, CPA, CFO/COO Linas is responsible for the financial matters and general operations of HInext. Linas is well versed in accounting and marketing matters. He got his CA designation at Ernst & Young. Linas held various financial, tax and operational roles throughout his career. Most recently he lead all marketing activities for Toyota in Canada for Toyota, Lexus and Scion Divisions. Linas is also a direct investor in Hinext. Peggy Lucas, Senior Sales Director Peggy is responsible mainly for Business Development at HInext. Peggy has been instrumental in getting new clients for the firm and has generated north of $3 million in sales for the firm over the last couple of years. Peggy is responsible for responding to RFPs, communication with clients and creating partnership channels. She is spearheading the expansion into the US market and has signed a significant US distributor agreement that has generated substantial traction for the Company in the US Peggy has a Masters in Development studies from the London School of Economics.
Linas Balaisis
CFO/COO 

Horizon Technology Finance United States

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Year Founded
2003
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jerry Michaud

Hub Angels Investment Group

Hub Angels Investment Group is an angel group that was founded in 2 and is based in Cambridge Massachusetts. The firm manages a fund structure and recently closed its 4th fund making the total AUM of the group around $4 million. The firm makes investments ranging from $25 to $5 in equity for companies that are at least 12 months old. The firm makes investments ranging from four to eight years and prefers to invest in companies whose valuation does not exceed $1 million. Hub angels plans on making approximately 3 allocations over the next 6-9 months with stated interest in diagnostics and medical device companies.
Randy Barko
Member 

Jump Capital United States

Jump Capital was founded in 2012 and is based in Chicago, with an additional office in San Francisco. The firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, Jump Capital typically allocates $2-15 million, and prefers to invest in Series B-C rounds. Jump Capital invests in the USA and Canada, and has previously invested in 6 healthcare companies.

Jump Capital invests in medical devices, diagnostics, digital and mobile health, and healthcare services. The firm is open to opportunities in any clinical indication. Jump Capital is only interested in devices and diagnostics that have in-human data.

Dr Garrett Vygantas
LinkedIn logo Partner 

JVC Investment Partners United States

JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

David Jonas
Founder, President & CEO 
Jonathan Jonas
Partner 

Life Science Angels

Life Science Angels Inc was founded in 2004 and is based in Sunnyvale CA. The group makes early-stage equity investments in a wide range of life science companies. Life Science Angels invests primarily in California but is open to investing out of state provided a round is being syndicated with a local angel group. Life Science Angels does not rule out investing outside the USA but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied but are usually of about $2-$6, Life Science Angels usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Dr Faz Bashi
Chair Digital Health & Sciences 
Karl Handelsman
Founder & Chairman 
Allan May
Founder 

Life Science Equity Partners

Life Science Equity Partners is a private equity firm based in Palo Alto California. The firm is solely focused on life science investments. The firm will invest in companies at all stages including early-stage companies with products still in development and late-stage companies with revenue. The firm typically makes early stage investments with a 1 year exit strategy in mind. The investment size is highly variable depending on the stage of the company. The firm has the ability to invest globally with typical allocations made to companies in North America. The firm is actively seeking new investment opportunities.
Michael Bianco
General Partner 

Life Science Nation

Life Science Nation (LSN) is the premier sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient. 

Biotech Phase of Development
Medtech Phase of Development
Unique Capabilities

Life Science Investor Profiles, LSN has sourced validated and maintains the largest global database of investor profiles. LSN defined 10 categories of Life Science Investor;

·         Private Equity

·         Venture capital

·         Family Offices

·         Corporate VC

·         Angel Groups

·         Large Pharma/ Biotech

·         Alternative Institutional Investors: Pensions, Endowments

·         Endowments/Foundations

·         Hedge Funds

·         Government Grants

Marketing Services, LSN consults on branding, messaging, and outbound marketing strategies. This includes developing a tagline, elevator pitch, executive summary, corporate power point presentation, and new or updated website design to fit your brand and message. LSN will develop a Global Target List of prequalified candidates to target for marketing initiatives.

Alejandro Zamorano
Tom Crosby
David Mejia
Gwen Lamar
Danielle Silva
Jack Fuller
Marlo Galvez
Laura Chess
Dennis Ford
BIO

Dennis is the founder and CEO of Life Science Nation (LSN) and creator of the Redefining Early Stage Investment (RESI) conference series. Most recently, he launched a broker-dealer entity called Boston Innovation Capital (BIC).

Dennis’s expertise is in creating and facilitating interactive dialogue between buyers and sellers. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. LSN provides a Match.com-like platform of product and services for scientist/entrepreneurs and early stage investors to connect with each other.

Dennis is the author of The Peddler’s Prerogative, The Fund Manager’s Marketing Manifesto, and most recently, The Life Science Executive’s Fundraising Manifesto. Dennis is an expert in sales, marketing, and business development. Dennis has distinct value in understanding the world of global alternative life science investors and how that relates to financing early stage technologies.

Life Sciences Alternative Funding United States

Life Sciences Alternative Funding (LSAF) founded in 213 is a direct investment firm based in White Plains New York. The firm focuses exclusively on providing debt capital for commercial-stage medical technology companies. The firm can allocate between USD 1M-5M per investment. The firm looks to provide flexible ?tailor-made? financing solution to companies. The firm can invest globally and is currently seeking new investment opportunities.

Steve DeNelsky
President